SUPN

#1841
Supernus Pharmaceuticals, Inc. - Common Stock
43.7 3 USD
-0.01%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
43.73
43.73
Jahresspanne
42.45
59.68
Tagesänderung
-1.04%
Monatliche Änderung
-13.32%
6 month change
-19.00%
Jahresänderung
-19.02%
Vorheriger Schlusskurs
44.1 9
Open
43.7 3
Tief
43.7 3
Hoch
43.7 3
Volumen
115
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K

SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026

Full document

Business Context and Reporting Period

Company: Supernus Pharmaceuticals, Inc. (SUPN)
Filing Type: Form 8-K (Current Report)
Date of Report: August 3, 2026
Event: Announcement of a conference call and webcast regarding the proposed merger with Indivior Pharmaceuticals Inc.

Key Financial Metrics

This filing is a current report regarding a corporate event and does not contain financial statements. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.

Material Changes

The primary material event is the advancement of the proposed merger between Supernus and Indivior. The companies are hosting a presentation to discuss the transaction details. No financial performance changes are reported in this specific filing.

Guidance, Outlook, and Risks

Outlook and Management Commentary:

  • Management intends to present information on the proposed merger of equals during the August 3, 2026, conference call.
  • A definitive joint proxy statement/prospectus will be filed with the SEC and sent to stockholders of both companies.
  • Investors are urged to read the joint proxy statement/prospectus for important information regarding the transaction.
Risks and Contingencies:
  • Transaction Completion: The merger may not be completed in a timely manner or at all due to regulatory delays, failure to obtain stockholder approval, or failure to satisfy closing conditions.
  • Market and Operational Risks: Risks include the impact of the transaction on stock prices, business disruption, diversion of management attention, and difficulties in integrating the two businesses.
  • Financial Risks: Potential effects of additional indebtedness incurred to fund a Special Dividend and the risk that anticipated synergies may not be realized.
  • Legal and Tax Risks: Possibility of stockholder litigation, termination fees, and the risk that the merger may not qualify as a tax-free reorganization.

Investor Verification Checklist

  • Verify the availability and contents of the upcoming joint proxy statement/prospectus (Form S-4) filed by Indivior and Supernus.
  • Review the investor presentation (Exhibit 99.1) referenced in this filing for specific merger terms and financial projections.
  • Monitor regulatory approval status and stockholder voting requirements for the proposed transaction.
  • Assess the potential impact of the Special Dividend and associated indebtedness on the combined entity's balance sheet.

Nachrichten